Color VEPs in Parkinson's disease

Barbato, Luca; Rinalduzzi, Steno; Laurenti, Maria Elena; Ruggieri, Stefano; Accornero, N.

doi:10.1016/0168-5597(94)90057-4

Cited by 43 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Evoked responses to coloured stimuli are also affected in PD [43] supporting the hypothesis that dopamine modulates the retinal colour system. In idiopathic PD, for example, amplitude is decreased and latency increased for all chromatic stimuli and especially for those using blue-yellow (B-Y) horizontal gratings [44], and this test may be a simple tool for distinguishing different parkinsonian syndromes.…”

Section: Visual Symptoms In Parkinson's Diseasementioning

confidence: 76%

Visual Symptoms in Parkinson's Disease

Armstrong

2011

Parkinson's Disease

130

View full text Add to dashboard Cite

Parkinson's disease (PD) is a common disorder of middle-aged and elderly people in which degeneration of the extrapyramidal motor system causes significant movement problems. In some patients, however, there are additional disturbances in sensory systems including loss of the sense of smell and auditory and/or visual problems. This paper is a general overview of the visual problems likely to be encountered in PD. Changes in vision in PD may result from alterations in visual acuity, contrast sensitivity, colour discrimination, pupil reactivity, eye movements, motion perception, visual field sensitivity, and visual processing speeds. Slower visual processing speeds can also lead to a decline in visual perception especially for rapidly changing visual stimuli. In addition, there may be disturbances of visuospatial orientation, facial recognition problems, and chronic visual hallucinations. Some of the treatments used in PD may also have adverse ocular reactions. The pattern electroretinogram (PERG) is useful in evaluating retinal dopamine mechanisms and in monitoring dopamine therapies in PD. If visual problems are present, they can have an important effect on the quality of life of the patient, which can be improved by accurate diagnosis and where possible, correction of such defects.

show abstract

Section: Visual Symptoms In Parkinson's Diseasementioning

confidence: 76%

Visual Symptoms in Parkinson's Disease

Armstrong

2011

Parkinson's Disease

130

View full text Add to dashboard Cite

show abstract

“…Both findings again suggest a degenerative process in the retina of PD affected subjects as well as in rotenone treated animals. Resulting from the retinal alterations, PD subjects have reduced contrast sensitivity and reduced colour discrimination which is progressive over time but can be improved with L-DOPA (Kupersmith et al, 1982;Smith et al, 1985;Price et al, 1992;Barbato et al, 1994). As a decrease in the number of DA amacrine cells has already been described in other animal models of PD, like MPTP treated monkeys (Ghilardi et al, 1988), we suggest that chronic rotenone application is a suitable model to mimic PD that has been -at least partiallyinduced by environmental toxins.…”

Section: The Density Of Retinal Da-ergic Cells Is Decreased In Rotenomentioning

confidence: 98%

A rat model of Parkinsonism shows depletion of dopamine in the retina

Biehlmaier

Alam

Schmidt

2007

Neurochemistry International

View full text Add to dashboard Cite

A rat model of Parkinsonism shows depletion of dopamine in the retina AbstractThe retinal dopamine (DA) deficiency is an important feature of the pathogenesis in Parkinson's disease (PD) visual dysfunction. Systemic inhibition of complex I (rotenone) in rats has been proposed as a model of PD. In this study, we investigated whether systemic inhibition of complex I can induce impairment of DA-ergic cells in the retina, similar to the destruction of retinal cells found in PD patients. Rotenone (2.5mg/kg i.p., daily) was administered over 60 days. Neurochemically, rotenone treated rats showed a depletion of DA in the striatum and substantia nigra (SN). In addition, the number of retinal DA-ergic amacrine cells was significantly reduced in the rotenone treated animals. This study is the first one giving highlight towards a deeper understanding of systemic complex I inhibition (rotenone as an environmental toxin) and the connection between both, DA-ergic degeneration in the nigrostriatal pathway, and in the DA-ergic amacrine cells of the retina.Retinal degeneration in a rotenone PD model This study is the first one giving highlight towards a deeper understanding of systemic complex I inhibition (rotenone as an environmental toxin) and the connection between both, DA-ergic degeneration in the nigrostriatal pathway, and in the DA-ergic amacrine cells of the retina.

show abstract

“…Treatment with dopaminergic drugs was shown to reverse the delays in visual evoked potentials (VEPs) in PD patients (Bodis-Wollner and Yahr 1978;Onofrj et al 1986;Bulens et al 1987;Barbato et al 1994). Therefore, initially, retinal dopaminergic alterations were claimed to be responsible for the visual changes in Parkinsonians, but later evidence appeared that there might be some additional pathology beyond the retina affecting the visual responses (Onofrj et al 1986;Bulens et al 1987;Buttner et al 1996;Bodis-Wollner 1997).…”

Section: Introductionmentioning

confidence: 98%

The Effect of Docosahexaenoic Acid on Visual Evoked Potentials in a Mouse Model of Parkinson’s Disease: The Role of Cyclooxygenase-2 and Nuclear Factor Kappa-B

et al. 2011

View full text Add to dashboard Cite

This study aimed to investigate the effect of docosahexaenoic acid (DHA) on visual evoked potentials (VEPs) in a mice model of Parkinson's disease (PD). Mice model was created by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and DHA was given by gavage. Cyclooxygenase-2 (COX-2), caspase-3 activities, nuclear factor kappa-B (NF-κB) and prostaglandin E2 (PGE2) levels were determined in substantia nigra (SN) and retina. Cyclooxygenase-2 intensities were also determined immunohistochemically. The tyrosine hydroxylase (TH) immunolabelling was significantly decreased in MPTP group compared to control. Docosahexaenoic acid decreased dopaminergic neuron death in MPTP + DHA group when compared to MPTP group. Mice treated with MPTP showed motor deficits as compared to control. Significant improvement was observed in MPTP + DHA group when compared to MPTP group. Treatment with MPTP significantly increased the activity of COX-2 and total COX in SN when compared to the control group. Docosahexaenoic acid caused a significant decrease in total COX and COX-2 activity in SN of mice given MPTP. Cyclooxygenase-2 showed strong immunostaining in MPTP group when compared to other groups in SN. Levels of PGE2 increased in MPTP group when compared to control in SN. Docosahexaenoic acid treatment in MPTP group reduced PGE2 in SN. Nuclear factor kappa-B levels were found to be decreased in SN of MPTP group. The mean latencies of P1, N1, P2, N2, P3, N3, P4, N4, and P5 VEP components were significantly prolonged in MPTP group when compared to control. In MPTP + DHA group, the mean latencies of all components except P5 returned to control values. Current data shows that DHA treatment improves prolonged VEPs latencies and locomotor activity.

show abstract

Color VEPs in Parkinson's disease

Cited by 43 publications

References 12 publications

Visual Symptoms in Parkinson's Disease

Visual Symptoms in Parkinson's Disease

A rat model of Parkinsonism shows depletion of dopamine in the retina

The Effect of Docosahexaenoic Acid on Visual Evoked Potentials in a Mouse Model of Parkinson’s Disease: The Role of Cyclooxygenase-2 and Nuclear Factor Kappa-B

Contact Info

Product

Resources

About